A novel BTK inhibitor BGB-3111: new data presented at ASH 2017

Constantine Tam

Constantine Tam, MD, from the Peter MacCallum Cancer Centre, Melbourne, Australia tells us about a novel BTK inhibitor, BGB-3111 and how it might compare with existing treatments, such as ibrutinib. Results from three studies on the agent were presented at the ASH 2017 meeting in Atlanta, GA, and Constantine gives us a summary of the data.

Share this video  
Similar topics
Related videos
1:57
The state of CAR T-cell products today
Nitin Jain
1:28
Ibrutinib and venetoclax: a powerful combination in frontline and relapsed CLL
Nitin Jain
2:42
iFCG yields unprecedented MRD negativity in CLL
Nitin Jain
2:14
Novel approaches to first line CLL treatment
Nitin Jain
1:15
CAR T across hematological malignancies: trials to watch
John Rossi
Chronic Lymphocytic Leukemia
BGB-3111, Zanubrutinib
ASH 2017
Interview
More from Constantine Tam
First results from Bgb-3111 in CLL and Waldenström’s macroglobulinemia
Next steps for the use of ibrutinib and venetoclax for the treatment of lymphoma
Why should young investigators join the CLL community?
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals